Blood-pressure reduction and cardiovascular risk in HOPE study

Lancet

Volumn 358, Issue 9299, 2001, Pages 2130-2131

  Sleight, Peter ^a,b   Yusuf, Salim ^b   Pogue, Janice ^c   Tsuyuki, Ross ^d   Diaz, Rafael ^e   Probstfield, Jeffrey ^f  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b HAMILTON GENERAL HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e Instituto Cardiovascular de Rosario   (Argentina)

^f Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RAMIPRIL;

ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; HEART INFARCTION; HEART VENTRICLE FUNCTION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 0035936402     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)07186-0     Document Type: Article

References (5)

1. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients
2. Epidemiology: Blood pressure, stroke, and coronary heart disease
3. The HOPE study: Comparison with other trials of secondary prevention
4. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
5. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials